CD20 Antibody (B-LY1): sc-19990

CD20 Antibody (B-LY1) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD20 protein of human origin by immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD20 (B-LY1) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD20 protein is a crucial leukocyte surface antigen characterized by four transmembrane domains and cytoplasmic N- and C-termini, which play significant roles in cellular signaling. Notably, CD20′s cytoplasmic domain contains multiple phosphorylation sites that can lead to the generation of different isoforms, thereby influencing functional diversity. CD20 is predominantly expressed on B cells, but has also been identified on both normal and neoplastic T cells, highlighting relevance in various immune responses and pathologies. Functionally, CD20 acts as a calcium-permeable cation channel, facilitating transition from G0 to G1 phase of the cell cycle in response to insulin-like growth factor 1 (IGF-1). This activation is mediated through IGF-1 receptor and involves alpha subunits of heterotrimeric G proteins, ultimately leading to increased DNA synthesis, which is thought to be regulated by basic helix-loop-helix leucine zipper transcription factors. CD20′s ability to modulate cell cycle progression underscores importance in both normal immune function and pathogenesis of B-cell malignancies, making anti-CD20 antibody (B-LY1) an essential tool for research and therapeutic applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD20 Antibody (B-LY1) References:

1. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.  |  Gelfand, JM., et al. 2017. Neurotherapeutics. 14: 835-841. PMID: 28695471
2. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.  |  Bacac, M., et al. 2018. Clin Cancer Res. 24: 4785-4797. PMID: 29716920
3. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.  |  de Sèze, J., et al. 2023. Front Immunol. 14: 1004795. PMID: 37033984
4. Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis.  |  Baker, D., et al. 2024. Mult Scler Relat Disord. 82: 105400. PMID: 38181696
5. scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells.  |  Ji, L., et al. 2024. Cancer Lett. 584: 216664. PMID: 38253219
6. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.  |  Carlson, AK., et al. 2024. Drugs. 84: 285-304. PMID: 38480630
7. CD20: a regulator of cell-cycle progression of B lymphocytes.  |  Tedder, TF. and Engel, P. 1994. Immunol Today. 15: 450-4. PMID: 7524522
8. CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia.  |  Smiers, FJ., et al. 1996. Br J Haematol. 93: 125-30. PMID: 8611444
9. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells.  |  Algino, KM., et al. 1996. Am J Clin Pathol. 106: 78-81. PMID: 8701937
10. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.  |  Szöllósi, J., et al. 1996. J Immunol. 157: 2939-46. PMID: 8816400
11. Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I.  |  Kanzaki, M., et al. 1997. J Biol Chem. 272: 4964-9. PMID: 9030557
12. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes.  |  Himmelmann, A., et al. 1997. Blood. 90: 3984-95. PMID: 9354667

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD20 Antibody (B-LY1) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-CD20 Antibody (B-LY1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD20 Antibody (B-LY1) Specifications

Alternate Product Name: CD20

Product Clone Name: B-LY1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD20

Epitope Species: human

Product Reactivity/Detection: an epitope located on the surface of B-cells

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for CD20 Antibody (B-LY1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin